Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gardasil

The HPV Vaccine Prevents Cervical Cancer, So Why Are Indian Parents Still Saying No?

What the HPV vaccine actually does inside the bodyThe vaccine does not treat an existing infection. It trains the immune system to recognise and destroy the human papillomavirus before it can establish itself. Two strains, HPV 16 and HPV 18, cause roughly 70 percent of all cervical cancer cases globally.…

Times Life

HIV-Positive Patients Face a Much Higher Risk of Anal Cancer, Study Finds

HIV raises anal cancer risk by 8.6 times when poorly controlled and 3.9 times even with good control. Proven screening and vaccination tools exist. Here's what HIV patients need to know.

Medical Daily

RFK Jr.'s vow to overhaul vaccine injury program echoes grievances of anti-vaccine movement

Health Secretary Robert F

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Benzinga

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Benzinga

Merck: 4 No-Brainer Reasons to Buy This Dip

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

MarketBeat

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

Read news from The Economist, FT, and more,
with one subscription

How RFK Jr. drove mistrust of a cancer prevention vaccine - Roll Call

President-elect Donald Trump's pick to lead HHS has a long history of discounting and peddling misinformation about the HPV vaccine.

Roll Call

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products. Pharmaceutical sales growth, excluding Lagevrio sales, was…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Children Health Defense

40 stories

The Indian Council of Medical Research

35 stories

Animal Health

21 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.